Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid

Autor: L. Parnetti, L. Ambrosoli, G. Abate, C. Azzini, R. Balestreri, L. Bartorelli, A. Bordin, G. Crepaldi, G. Cristianini, D. Cucinotta, M. Cuzzupoli, O. Candia, F. Fabris, M. Maggioni, R. Scarpa, C. Villardita, R. Girardello, A. Poli, U. Senin
Rok vydání: 2009
Předmět:
Male
medicine.medical_specialty
Cytidine Diphosphate Choline
Cholinergic Agents
Ascorbic Acid
adverse effects/analogs /&/ derivatives/pharmacology/therapeutic use
Neuropsychological Tests
Placebo
Severity of Illness Index
law.invention
Double-Blind Method
Randomized controlled trial
Alzheimer Disease
law
Rating scale
diagnosis/drug therapy
Internal medicine
Severity of illness
medicine
Humans
Thyrotropin-Releasing Hormone
Aged
business.industry
Brain
Aged
Alzheimer Disease
diagnosis/drug therapy
Ascorbic Acid
adverse effects/therapeutic use
Brain
drug effects
Cholinergic Agents
adverse effects/therapeutic use
Cytidine Diphosphate Choline
adverse effects/therapeutic use
Double-Blind Method
Female
Humans
Male
Neuropsychological Tests
Severity of Illness Index
Thyrotropin-Releasing Hormone
General Medicine
medicine.disease
Ascorbic acid
Surgery
adverse effects/therapeutic use
Neurology
Tolerability
drug effects
Female
Neurology (clinical)
Alzheimer's disease
business
Citicoline
medicine.drug
Zdroj: Acta Neurologica Scandinavica. 92:135-140
ISSN: 1600-0404
0001-6314
DOI: 10.1111/j.1600-0404.1995.tb01027.x
Popis: Introduction - Posatirelin (L-pyro-2-amino adipyl-L-leucil-L-prolinamide) a new synthetic tripeptide with cholinergic, catecholaminergic and neurotrophic properties, was investigated in the treatment of Alzheimer's disease. Material and methods - A multicentre, double-blind study vs citicoline (reference drug) and ascorbic acid (inactive drug) was carried out in elderly patients suffering from late-onset Alzheimer's disease. The once daily intramuscular treatment lasted for three months followed by one-month oral treatment with a placebo. Subscales and factors of GBS (Gottfries-Brane-Steen) Rating Scale were identified as primary measures for efficacy assessment. Results - At the end of the treatment, GBS subscale and factor scores assessing intellectual and emotional impairments, orientation and memory, ability to perform activities of daily living, depression-anxiety, attention and motivation were improved in the posatirelin group, showing significant differences with respect to the citicoline and/or ascorbic acid groups. Tolerability was good in all groups. Conclusions - The improvement in the GBS Rating Scale scores observed in the posatirelin group is clinically relevant. It is worth verifying the drug-induced functional improvements, in further studies with large samples.
Databáze: OpenAIRE
Externí odkaz: